Taranabant

Drug Profile

Taranabant

Alternative Names: MK-0364

Latest Information Update: 02 Jun 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Class Amides; Obesity therapies; Pyridines
  • Mechanism of Action Cannabinoid 1 receptor inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Obesity; Psychiatric disorders; Smoking withdrawal

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 03 Oct 2008 Discontinued - Phase-III for Obesity in USA, Australia, Austria, Czech Republic, Denmark, Finland, France, Germany, New Zealand and Sweden (PO)
  • 01 Apr 2008 Interim efficacy and adverse events data from a phase III trial in Obesity presented at the 57th Annual Scientific Session of the American College of Cardiology (ACC-2008) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top